News and Announcements
4Dx Visits London and Participates in the House of Lords Event
- Published March 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
4Dx is pleased to inform you that Chairman and CEO, Andreas Fouras, will be lead speaker at a lunchtime debate at the All Party Parliamentary Engineering Group ‘APPEG’ in the House of Lords, London on Tuesday 21st March. The debate series represents a plank of the APPEG program to enable contact and involvement between parliamentarians and the engineering profession.
KEY TAKEAWAYS:
- Professor the Lord Broers, Co-Chair of the Group, will introduce the debate on exciting advances in medical imaging.
- “We are delighted to have Professor Fouras, Chairman and CEO of medical technology company 4Dx, who founded this life-changing medical technology company, which aims to augment the capabilities of respiratory diagnostics currently available, leveraging information that has until now remained hidden in X-ray images.”
- 4Dx Executive Director, Steve Peuschel, is currently in London with Andreas as part of a global 4Dx roadshow presenting data, from the first 4Dx in-human study, to a wide range of organizations key to the company’s strategy.
In addition, the company delivered presentations in Washington DC to the Cystic Fibrosis Foundation – the U.S. peak body for Cystic Fibrosis research. The 4Dx roadshow now continues in Europe with industry and potential hospital partners, a key focus of the latter half of the trip.
4Dx Limited is an early stage medical technology company based in Melbourne, Australia, established to commercialise four-dimensional lung imaging technology: 4DxV.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
